// App-Quantinova.ai

420 : Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).

Researchers

Presenter

  • Talia Golan

Principal Investigators

  • Hedy L. Kindler

  • Philipp Schatz

  • Teodora Goranova

  • Gershon Y. Locker

  • Karen Cui

  • Katia Schlienger

  • David McGuinness

  • J. Andrew Williams

  • Maria Orr

  • Thorsten Gutjahr

  • Yu-Zhen Liu

Medical Centers

  • The Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel

  • The University of Chicago Medical Center, Chicago, IL

  • AstraZeneca, Gothenburg, Sweden

  • AstraZeneca, Gaithersburg, MD

  • Merck & Co., Inc., Kenilworth, NJ

Locations

  • Israel

  • United States

  • Sweden

  • United Kingdom

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Breast cancer type 1 susceptibility protein

  • Breast cancer type 2 susceptibility protein

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT02184195

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved